Management of Elevated Diastolic Blood Pressure (≥90 mm Hg)
For adults with consistently elevated diastolic blood pressure ≥90 mm Hg, initiate prompt combination pharmacological therapy with lifestyle modifications, using a two-drug regimen of a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium channel blocker or thiazide/thiazide-like diuretic, preferably as a single-pill combination. 1
Initial Evaluation and Confirmation
Before initiating treatment, confirm the diagnosis through proper blood pressure measurement:
- Obtain out-of-office blood pressure monitoring (ambulatory or home BP monitoring) when clinic BP is ≥140/90 mm Hg, as out-of-office measurements are stronger predictors of cardiovascular outcomes 2
- Assess 10-year ASCVD risk to guide treatment intensity and follow-up intervals 1
- Screen for secondary hypertension in adults diagnosed before age 40 (except obese patients, where obstructive sleep apnea evaluation takes priority) 1
- Evaluate for target organ damage including assessment of kidney function, albuminuria, and cardiovascular complications 1
Treatment Initiation Based on Blood Pressure Stage
Stage 1 Hypertension (DBP 90-99 mm Hg)
Low cardiovascular risk (<10% 10-year ASCVD risk):
- Begin with nonpharmacological therapy alone 1
- Reassess BP within 3-6 months 1
- If BP remains ≥140/90 mm Hg after 3 months of lifestyle intervention, add pharmacological therapy 1
High cardiovascular risk (≥10% 10-year ASCVD risk):
- Initiate combination therapy immediately with both nonpharmacological and pharmacological treatment 1
- Reassess BP within 1 month 1
Stage 2 Hypertension (DBP ≥100 mm Hg)
- Start combination therapy with two antihypertensive agents of different classes immediately 1
- Refer to or evaluate by primary care provider within 1 month 1
- Combine with intensive lifestyle modifications 1
Hypertensive Emergency (DBP ≥110 mm Hg)
- Requires prompt evaluation and immediate antihypertensive treatment 1
- Treatment should be initiated within 1 week at minimum, but urgency depends on presence of acute target organ damage 1
Pharmacological Treatment Strategy
First-Line Drug Classes
The following four drug classes have demonstrated the most effective reduction in BP and cardiovascular events 1:
- ACE inhibitors
- Angiotensin receptor blockers (ARBs)
- Dihydropyridine calcium channel blockers
- Thiazide/thiazide-like diuretics (chlorthalidone, indapamide)
Recommended Combination Regimens
Initial two-drug combination (preferred approach for most patients with confirmed hypertension ≥140/90 mm Hg): 1
- RAS blocker (ACE inhibitor OR ARB) + dihydropyridine calcium channel blocker, OR
- RAS blocker (ACE inhibitor OR ARB) + thiazide/thiazide-like diuretic
Use fixed-dose single-pill combinations to improve adherence 1
If BP remains uncontrolled on two drugs:
- Escalate to three-drug combination: RAS blocker + dihydropyridine calcium channel blocker + thiazide/thiazide-like diuretic 1
- Preferably as a single-pill combination 1
Critical Medication Warnings
Never combine two RAS blockers (ACE inhibitor + ARB) as this is potentially harmful 1
Beta-blockers should be reserved for compelling indications (angina, post-MI, heart failure with reduced ejection fraction, heart rate control) and combined with other major BP-lowering drug classes 1
Blood Pressure Targets
General Adult Population
Target treated systolic BP to 120-129 mm Hg in most adults, provided treatment is well tolerated 1
For diastolic BP:
- Target <90 mm Hg for adults aged 30-59 years 1
- Target <80 mm Hg is reasonable for most patients as part of overall BP control <140/90 mm Hg 1
Special Populations
Diabetes:
- Target systolic BP to 130 mm Hg and <130 mm Hg if tolerated, but not <120 mm Hg 1
- In older adults ≥65 years with diabetes, target systolic BP 130-139 mm Hg 1
Chronic kidney disease:
- Target systolic BP 130-139 mm Hg 1
- In moderate-to-severe CKD with eGFR >30 mL/min/1.73 m², target systolic BP 120-129 mm Hg if tolerated 1
- Use RAS blockers as part of treatment strategy when albuminuria or proteinuria is present 1
Pregnancy:
- In chronic or gestational hypertension, lower BP below 140/90 mm Hg but not below 80 mm Hg for diastolic BP 1
Lifestyle Modifications (Essential for All Patients)
Implement the following evidence-based interventions 1:
- Weight management: Target BMI 20-25 kg/m² and waist circumference <94 cm (men) or <80 cm (women)
- Dietary changes: Adopt Mediterranean or DASH diet patterns
- Alcohol restriction: Limit to <100 g/week of pure alcohol (preferably avoid completely)
- Sugar reduction: Restrict free sugar to maximum 10% of energy intake; avoid sugar-sweetened beverages
- Physical activity: Regular aerobic exercise complemented with resistance training 2-3 times/week
- Smoking cessation: Complete tobacco cessation with supportive care
Follow-Up Schedule
- Stage 1 hypertension with low CVD risk: Reassess in 3-6 months 1
- Stage 1 hypertension with high CVD risk: Reassess in 1 month 1
- Stage 2 hypertension: Reassess in 1 month 1
- Normal BP: Annual screening is reasonable 1
Common Pitfalls to Avoid
Inadequate BP measurement technique: Always confirm elevated readings with out-of-office monitoring to exclude white coat hypertension 2
Monotherapy initiation: Most patients require combination therapy from the start; monotherapy leads to inadequate control 1
Suboptimal dosing: Use maximum or optimal dosages of medications before adding additional agents 3
Medication nonadherence: Address by using single-pill combinations and taking medications at the most convenient time for the patient to establish routine 1
Ignoring lifestyle factors: Pharmacological therapy alone is insufficient; lifestyle modifications are essential for all patients 1
Overly aggressive lowering in older adults: In patients ≥85 years, consider individual tolerability and avoid excessive BP reduction 1
Failure to screen for secondary causes: Particularly important in adults diagnosed before age 40 1